Early data for BCL6 degraders in DLBCL is highly promising, representing a new class of targeted therapy. This approach, similar to degraders in breast and prostate cancer, could become a significant future treatment beyond established pathways.
Despite the POLARIX trial showing greater benefit for Pola-R-CHP in non-GCB DLBCL, experts don't use this biomarker for treatment decisions. The community's IHC-based testing is considered too discordant with the trial's GEP method to be clinically reliable.
Experts predict that emerging cell-free DNA (ctDNA) tests for lymphoma will shift treatment from fixed durations to a response-adapted approach. Monitoring minimal residual disease via ctDNA will allow clinicians to tailor the length of therapy based on the quality of response.
The TRANSFORM study quantifies the critical importance of therapy timing. DLBCL patients receiving Liso-cel CAR-T as a second-line treatment had a 95% two-year overall survival, which dropped significantly to 78% for patients who received it third-line after crossover from the standard-of-care arm.
Experts vehemently state that patients ineligible for autologous stem cell transplant are not necessarily ineligible for CAR-T therapy. This corrects a critical misconception, urging community oncologists to refer these patients for CAR-T evaluation as they may still be candidates.
It's a myth that patients must have active disease to receive their manufactured CAR-T cells. Data from the TRANSFORM study shows that patients who achieved a complete response with bridging therapy while awaiting cell manufacturing still proceeded with the infusion and benefited.
Based on data showing CRS and ICANS are extremely rare beyond two weeks post-infusion, regulatory requirements for CAR-T have been significantly eased. The mandatory monitoring period at the treatment center has been cut from 30 days to 14, and the driving restriction has been reduced from eight weeks to two.
Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.
An oncologist used ChatGPT to find the year's most important paper and it suggested a study on adjuvant exercise in colorectal cancer that wasn't on his list. This highlights AI's potential in research discovery and challenging expert assumptions.
A 15-year follow-up of a SWOG clinical trial shows a significant portion of follicular lymphoma patients treated with R-CHOP remain disease-free. This challenges the long-held belief that the disease is incurable, shifting the paradigm towards a curative intent.
Combining the ADC Loncastuximab before a bispecific antibody may lower the bispecific's toxicity, potentially through a debulking effect. This surprising finding suggests a strategy to improve the tolerability and delivery of bispecifics, especially in community settings.
An expert treating DLBCL states they no longer use bispecific antibodies as monotherapy. Combining them with partners like chemotherapy (GemOx) or ADCs (Polatuzumab) raises the complete response rate by 15-20%, offering a better chance of benefit for patients.
Despite FDA warnings, the actual risk of developing a secondary T-cell lymphoma after CAR-T for lymphoma is exceedingly rare. Experts contextualize this as an anecdotal risk for a potentially curative therapy, with baseline germline abnormalities possibly predisposing some patients.
For third-line follicular lymphoma, where both CAR-T and bispecifics are approved, experts are leaning towards CAR-T. The long-term follow-up data for CAR-T suggests a potential for cure, making it a more compelling option for eligible patients despite logistical challenges.
In heavily pretreated relapsed/refractory follicular lymphoma, it's crucial to perform a tumor biopsy to check for CD20 expression before choosing a CD20-targeting bispecific antibody. Prior treatments can lead to loss of the antigen, which would render the bispecific ineffective.